Adam Richard, Duong Tim Q, Hodges Laura, Lu Jinyu, Maldjian Takouhie
Montefiore Medical Center, 111 E. 210th Street, Bronx, NY, 10467, USA.
Ann Med Surg (Lond). 2022 Nov 14;84:104900. doi: 10.1016/j.amsu.2022.104900. eCollection 2022 Dec.
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is an important prognostic indicator in breast cancer. Internal mammary lymph node involvement is not currently included in pCR determination, as sampling at the time of surgery is not routinely performed.
Pre and post neoadjuvant chemotherapy MRI or PET/CT imaging response of the internal mammary lymph node chain was utilized as a surrogate to pCR and imaging data was correlated with patient outcomes.
Internal mammary lymph node response to NAC was associated with disease free survival over the course of this study, regardless of whether axillary nodal pCR was achieved.
Internal mammary lymph nodal response to NAC is an important prognostic indicator. Potential use of internal mammary lymph node resolution as an imaging data input for AI models that predict pCR post-NAC may improve accuracy and other metrics in pCR prediction.
新辅助化疗（NAC）后的病理完全缓解（pCR）是乳腺癌的一个重要预后指标。目前，内乳淋巴结受累情况未纳入pCR的判定，因为手术时通常不常规进行内乳淋巴结取样。
利用新辅助化疗前后内乳淋巴结链的MRI或PET/CT成像反应作为pCR的替代指标，并将成像数据与患者预后相关联。
在本研究过程中，内乳淋巴结对NAC的反应与无病生存期相关，无论腋窝淋巴结是否达到pCR。
内乳淋巴结对NAC的反应是一个重要的预后指标。将内乳淋巴结消退情况作为预测NAC后pCR的人工智能模型的成像数据输入，可能会提高pCR预测的准确性和其他指标。
